ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
+12.59%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$366M
AUM Growth
+$143M
(+64%)
Cap. Flow
+$97.7M
Cap. Flow
% of AUM
26.67%
Top 10 Holdings %
Top 10 Hldgs %
59.33%
Holding
282
New
118
Increased
36
Reduced
44
Closed
29
Top Buys
| 1 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
$33.9M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$25.5M |
| 3 |
Protagonist Therapeutics
PTGX
|
$16.9M |
| 4 |
Roivant Sciences
ROIV
|
$16.2M |
| 5 |
Cytokinetics
CYTK
|
$15.9M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$23.2M |
| 2 |
Viking Therapeutics
VKTX
|
$19.7M |
| 3 |
Royalty Pharma
RPRX
|
$18.2M |
| 4 |
Merck
MRK
|
$7.09M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$6.35M |
Sector Composition
| 1 | Healthcare | 82.64% |
| 2 | Communication Services | 1.24% |
| 3 | Financials | 0.78% |
| 4 | Materials | 0.59% |
| 5 | Consumer Discretionary | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
TG Therapeutics
TGTX
$5.06B
| $66.3K | 0.02% |
+4,361
| New | +$66.3K |
|
152
Astria Therapeutics
ATXS
$395M
| $65.5K | 0.01% |
4,652
-186,599
| -98% | -$2.63M |
|
153
4D Molecular Therapeutics
FDMT
$309M
| $63.7K | 0.01% |
+2,000
| New | +$63.7K |
|
154
VanEck Gold Miners ETF
GDX
$19.4B
| $63.2K | 0.01% |
2,000
-1,000
| -33% | -$31.6K |
|
155
Lantheus
LNTH
$3.66B
| $62.2K | 0.01% |
+1,000
| New | +$62.2K |
|
156
Evotec
EVO
$1.2B
| $60.3K | 0.01% |
+7,700
| New | +$60.3K |
|
157
Kohl's
KSS
$1.84B
| $58.3K | 0.01% |
2,000
| – | – |
|
158
Disc Medicine
IRON
$2.09B
| $55.8K | 0.01% |
+896
| New | +$55.8K |
|
159
Krystal Biotech
KRYS
$4.33B
| $53.4K | 0.01% |
+300
| New | +$53.4K |
|
160
Regenxbio
RGNX
$476M
| $52.7K | 0.01% |
+2,500
| New | +$52.7K |
|
161
KraneShares CSI China Internet ETF
KWEB
$8.43B
| $52.5K | 0.01% |
2,000
| – | – |
|
162
FibroGen
FGEN
$45.7M
| $50.2K | 0.01% |
+854
| New | +$50.2K |
|
163
Ovid Therapeutics
OVID
$91.7M
| $50.2K | 0.01% |
16,446
+3,200
| +24% | +$9.76K |
|
|
IMA
164
ImageneBio, Inc. Common Stock
IMA
$94.5M
| $49.7K | 0.01% |
+2,917
| New | +$49.7K |
|
165
Amplify Energy
AMPY
$161M
| $46.8K | 0.01% |
7,081
| – | – |
|
166
Pharvaris
PHVS
$1.41B
| $46.2K | 0.01% |
+2,000
| New | +$46.2K |
|
167
Ultra Clean Holdings
UCTT
$1.08B
| $45.9K | 0.01% |
+1,000
| New | +$45.9K |
|
168
Akero Therapeutics
AKRO
$3.52B
| $45.6K | 0.01% |
1,807
-14,193
| -89% | -$359K |
|
169
Viridian Therapeutics
VRDN
$1.52B
| $44.7K | 0.01% |
+2,550
| New | +$44.7K |
|
|
ELEV
170
DELISTED
Elevation Oncology
ELEV
| $44.3K | 0.01% |
+8,629
| New | +$44.3K |
|
171
Pyxis Oncology
PYXS
$99.8M
| $42.6K | 0.01% |
+10,000
| New | +$42.6K |
|
172
Arcutis Biotherapeutics
ARQT
$1.94B
| $42.2K | 0.01% |
4,254
-270,746
| -98% | -$2.68M |
|
173
Denali Therapeutics
DNLI
$2.16B
| $41K | 0.01% |
+2,000
| New | +$41K |
|
174
Adverum Biotechnologies
ADVM
$66.5M
| $39.6K | 0.01% |
+2,800
| New | +$39.6K |
|
|
175
Merck
MRK
$210B
| $39.6K | 0.01% |
300
-53,700
| -99% | -$7.09M |
|